Compare Stocks: SLS, PRAX, PTGX, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$346.58 +2.8%	$347.03	$136.73 ▼ $382.54	$10.26B	0.53	327,522 shs	407,794 shs
PRAX Praxis Precision Medicines	$375.84 +3.1%	$325.63	$37.19 ▼ $392.70	$10.50B	2.78	442,788 shs	413,317 shs
PTGX Protagonist Therapeutics	$154.32 +2.4%	$134.70	$54.50 ▼ $160.81	$9.99B	1.78	488,124 shs	402,517 shs
SLS SELLAS Life Sciences Group	$15.46 +15.4%	$11.85	$1.39 ▼ $15.88	$3.12B	2.48	6.14 million shs	15.20 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	0.00%	+4.31%	+5.83%	+15.74%	+137.61%
PRAX Praxis Precision Medicines	0.00%	+2.46%	+16.58%	+9.40%	+730.59%
PTGX Protagonist Therapeutics	0.00%	-0.50%	+13.95%	+55.58%	+174.44%
SLS SELLAS Life Sciences Group	0.00%	+20.97%	+25.28%	+98.71%	+735.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$346.58 +2.8%	$347.03	$136.73 ▼ $382.54	$10.26B	0.53	327,522 shs	407,794 shs
PRAX Praxis Precision Medicines	$375.84 +3.1%	$325.63	$37.19 ▼ $392.70	$10.50B	2.78	442,788 shs	413,317 shs
PTGX Protagonist Therapeutics	$154.32 +2.4%	$134.70	$54.50 ▼ $160.81	$9.99B	1.78	488,124 shs	402,517 shs
SLS SELLAS Life Sciences Group	$15.46 +15.4%	$11.85	$1.39 ▼ $15.88	$3.12B	2.48	6.14 million shs	15.20 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	0.00%	+4.31%	+5.83%	+15.74%	+137.61%
PRAX Praxis Precision Medicines	0.00%	+2.46%	+16.58%	+9.40%	+730.59%
PTGX Protagonist Therapeutics	0.00%	-0.50%	+13.95%	+55.58%	+174.44%
SLS SELLAS Life Sciences Group	0.00%	+20.97%	+25.28%	+98.71%	+735.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	5.43% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$585.95	55.90% Upside
PTGX Protagonist Therapeutics	2.94	Moderate Buy	$140.53	-8.93% Downside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-35.32% Downside

Current Analyst Ratings Breakdown

Latest SLS, PRAX, PTGX, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/17/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$112.00 ➝ $178.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	PTGX Protagonist Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $170.00
8/10/2026	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$118.00 ➝ $173.00
8/10/2026	PTGX Protagonist Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRYS Krystal Biotech	$389.13M	26.36	$7.29 per share	47.54	$45.92 per share	7.55
PRAX Praxis Precision Medicines	$8.55M	1,227.30	N/A	N/A	$48.03 per share	7.83
PTGX Protagonist Therapeutics	$46.02M	216.99	N/A	N/A	$13.01 per share	11.86
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRYS Krystal Biotech	$204.83M	$7.98	43.43	37.15	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/4/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	149.83	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest SLS, PRAX, PTGX, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRYS Krystal Biotech	N/A	8.32	7.96
PRAX Praxis Precision Medicines	N/A	15.73	15.73
PTGX Protagonist Therapeutics	N/A	21.71	21.71
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRYS Krystal Biotech	86.29%
PRAX Praxis Precision Medicines	67.84%
PTGX Protagonist Therapeutics	98.63%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
KRYS Krystal Biotech	13.10%
PRAX Praxis Precision Medicines	3.00%
PTGX Protagonist Therapeutics	5.19%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
PTGX Protagonist Therapeutics	120	64.71 million	61.35 million	Optionable
SLS SELLAS Life Sciences Group	10	201.95 million	199.32 million	Not Optionable

SLS, PRAX, PTGX, and KRYS Headlines

Recent News About These Companies

Investors Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

August 23 at 1:20 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Decibel Cannabis Company (OtherDBCCF) and SELLAS Life Sciences Group (SLS)

August 22 at 7:06 AM | theglobeandmail.com

SLS stock clocks three straight weeks of gains on cancer vaccine spillover, REGAL trial data anticipation

August 22 at 7:06 AM | msn.com

Traders Purchase Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

August 21 at 3:19 PM | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10% Higher - Still a Buy?

August 21 at 2:59 PM | marketbeat.com

SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress

August 21 at 5:43 AM | finance.yahoo.com

Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial

August 17, 2026 | finance.yahoo.com

This One Data Readout Could Make Or Break Sellas Life Sciences Group

August 13, 2026 | seekingalpha.com

Sellas’ experimental drug SLS009 appears to be leading the CDK9 race, says Alliance Global – analyst sees about 200% upside potential

August 12, 2026 | msn.com

Investors Buy High Volume of SELLAS Life Sciences Group Put Options (NASDAQ:SLS)

August 12, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Time to Buy?

August 12, 2026 | marketbeat.com

SELLAS Life Sciences Group, Inc. $SLS is Dagco Inc.'s 10th Largest Position

August 12, 2026 | marketbeat.com

Sellas Life Sciences reports wider loss as REGAL trial nears final analysis

August 11, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

August 11, 2026 | marketbeat.com

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.8% - What's Next?

August 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires 221,957 Shares of SELLAS Life Sciences Group, Inc. $SLS

August 10, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 12.4% Higher - Time to Buy?

August 3, 2026 | marketbeat.com

SLS stock eyes green start to August after nearly $6M in fresh institutional buying: Retail stays bearish

August 3, 2026 | msn.com

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

August 2, 2026 | seekingalpha.com

SELLAS Life Sciences Group (SLS) Expected to Release Quarterly Earnings on Thursday

August 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, PRAX, PTGX, and KRYS Company Descriptions

Krystal Biotech NASDAQ:KRYS

$346.58 +9.56 (+2.84%)

As of 08/21/2026 04:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Praxis Precision Medicines NASDAQ:PRAX

$375.84 +11.26 (+3.09%)

As of 08/21/2026 04:00 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$154.32 +3.63 (+2.41%)

As of 08/21/2026 04:00 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

SELLAS Life Sciences Group NASDAQ:SLS

$15.46 +2.06 (+15.37%)

As of 08/21/2026 04:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, PRAX, PTGX, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, PRAX, PTGX, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, PRAX, PTGX, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, PRAX, PTGX, and KRYS Company Descriptions

Krystal Biotech NASDAQ:KRYS

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, PRAX, PTGX, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, PRAX, PTGX, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, PRAX, PTGX, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, PRAX, PTGX, and KRYS Company Descriptions

Krystal Biotech NASDAQ:KRYS

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools